Outsourced Drug Discovery
-
Outsourced Drug Discovery: Early Recovery Signals and Structural Demand Shifts
After several challenging years for outsourced drug discovery service providers, several headline indicators of demand are showing early signs of recovery. Biotech funding has grown and biopharma M&A has returned to growth, prompted in part by the looming patent cliff. Worldwide discovery and preclinical pipeline volumes have continued to expand. Together, these signals suggest a more constructive market environment than at any point since 2022.
-
Outsourced Drug Discovery: Building Differentiated Service Platforms
The outsourced drug discovery services market is becoming structurally more demanding for Western service providers while also creating clear opportunities for those willing to focus. As we described in our companion Executive Insights, the recovery in biotech funding masks structural shifts in how biopharma allocates R&D dollars: in particular a migration of pipeline growth to China, and a continued shift within Western research from less differentiated activities to specialist expertise.
